EZH2 and hepatocellular carcinoma: Functionally, dual pharmacological inhibition of <i>EZH2</i> (GSK126) and <i>LSD1</i> (SP2509) suppressed HCC cell proliferation, induced G1-phase arrest, and enhanced apoptosis, as evidenced by increased caspase-3/7 activity and decreased pro-caspase levels.